ATOSSA THERAPEUTICS, INC. (ATOS): Nasdaq/NYSE listing notice — Atossa receives Nasdaq minimum bid price deficiency notice; compliance period through Aug 20, 2025

ATOSSA THERAPEUTICS, INC.

Received Nasdaq deficiency notice on Feb 21, 2025 for failing to maintain $1.00 minimum bid price for 30 consecutive business days.
Compliance period ends Aug 20, 2025; possible additional 180-day extension if not compliant by then.
To regain compliance, common stock must close at $1.00+ for at least 10 consecutive business days.
Notice has no immediate effect on stock listing or trading; company monitoring and evaluating options.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ATOSSA THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

February 21, 2025, Atossa Therapeutics, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq, because the Company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Company has until August 20, 2025 to regain compliance with Nasdaq Listing Rule 5550(a)(2). In the event the Company does not regain compliance by then, the Company may b

View on SEC.gov

Browse all listing & compliance notices →

ATOSSA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-25-025596

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.